We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of the PET in the Diagnosis Strategy of FUO or Inflammatory Syndrome in Immunocompetent Patients FUO-TEP (FUO-TEP)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01200771
First Posted: September 14, 2010
Last Update Posted: February 19, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University Hospital, Limoges
  Purpose
Fever of unknown origin (FUO) and chronic inflammatory syndrome could be seen in many affections. The diagnostic process is still a challenge and could not be specified yet after several clinical studies performed by trained teams using two levels diagnostic procedures. For this reason, the diagnosis involves many additional and expensive tests such as computed tomography (CT scan), scintigraphic imaging, endoscopy, biopsy. There is no evidence-based recommendation for the diagnostic work-up of FUO or chronic inflammatory syndrome. Positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose combined with CT scan (FDG-PET/CT) is widely used in malignant diseases and seems to be promising for the diagnosis of inflammatory disorders. Its role has not been yet clearly defined in the investigation of FUO and chronic inflammatory syndrome.

Condition Intervention
Fever Procedure: TEP

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Impact of the PET-scan in the Diagnosis Strategy of Fever Unknown Origin or Inflammatory Syndrome in Immunocompetent Patients

Resource links provided by NLM:


Further study details as provided by University Hospital, Limoges:

Primary Outcome Measures:
  • To assess the contribution of FDG-PET/CT in the early diagnostic work-up of patients with FUO or chronic inflammatory syndrome [ Time Frame: 3 month ]

Secondary Outcome Measures:
  • To establish the role of FGD PET in reaching final diagnosis compared to conventional morphologic imaging modalities including computer tomography and gallium-67 citrate scintigraphy. [ Time Frame: 3 months ]
  • To evaluate sensitivity and specificity of this diagnostic procedure [ Time Frame: 3 months ]
  • To analyse the cost effectiveness of this diagnostic approach [ Time Frame: 3 months ]

Enrollment: 116
Study Start Date: May 2008
Study Completion Date: February 2014
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: TEP
    Intravenous injection of glucose labeled Fluor 18. The patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during wich the patient should not move.
Detailed Description:

All patients with FUO and chronic inflammatory syndrome will undergo FDG-PET/CT and conventional morphologic imaging modalities. Results of these two diagnostic procedures in identifying diagnostic clues will be compared.

We assume FDG-PET/CT could be safer and more helpful to reach early final diagnosis in patients with FUO and chronic inflammatory syndrome than conventional morphologic imaging modalities

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient with FUO criteria:

Fever since 3 weeks, Temperature > 38.3°C, No diagnostic after 3 days of hospitalization.

  • Patient with periodic fever criteria:

Fever with criteria like FUO, Fever-free intervals, and apparent remission of the underlying disease, At least 3 febrile episodes.

  • Inflammatory syndrome without any clinical sign, Important inflammatory syndrome: Erythrocyte sedimentation rate ≥ 50 at the first hour, and elevation of at least one another inflammatory parameter (haptoglobin, orosomucoïd, fibrinogen or C-reactive protein), Evolution since more than 3 weeks, No diagnostic orientation after clinical examination and history-taking, No diagnostic clue after 3 days of hospitalisation.
  • Oral informed consent obtained.

Exclusion Criteria:

  • Demented patient or unable to receive information on the protocol and to give informed consent.
  • Pregnant women, or without contraception.
  • Contraindication to iodine examination, gallium scintigraphy or 18FDG TEP-scan.
  • Immunodeficient patient.
  • Know HIV infection, neutropenic patient and nosocomial fever.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01200771


Locations
France
Médecine Interne - CHU
Amiens, France, 80080
Médecine Nucléaire - CHU
Amiens, France, 80080
Médecine Interne - CHU
Lille, France, 59037
Médecine Nucléaire et Imagerie Fonctionnelle - CHU
Lille, France, 59037
Médecine Interne - CHU
Limoges, France, 87042
Médecine Nucléaire - CHU
Limoges, France, 87042
Médecine Interne - AP-HP - Hôpital Hôtel Dieu
Paris, France, 75004
Médecine Nucléaire - AP-HP - Hôpital Hôtel Dieu
Paris, France, 75004
Médecine Interne - AP-HP - La Pitié Salpétrière
Paris, France, 75013
Médecine Nucléaire - AP-HP - La Pitié Salpétrière
Paris, France, 75013
Médecine Interne - AP-HP - Hôpital Cochin
Paris, France, 75014
Médecine Interne - AP-HP - Hôpital Bichat
Paris, France, 75018
Médecine Nucléaire - AP-HP - Hôpital Bichat
Paris, France, 75018
Service des Isotopes - CRLCC Centre Eugène Marquis
Rennes, France, 35042
Département de Médecine pour adulte - CHU
Rennes, France, 35056
Médecine Interne - CH
Rodez, France, 12000
Médecine Nucléaire - CH
Rodez, France, 12000
Médecine Interne - CHU
Toulouse, France, 31059
Médecine Nucléaire - CHU
Toulouse, France, 31059
Sponsors and Collaborators
University Hospital, Limoges
Investigators
Principal Investigator: Kim LY, MD University Hospital, Limoges
  More Information

Responsible Party: University Hospital, Limoges
ClinicalTrials.gov Identifier: NCT01200771     History of Changes
Other Study ID Numbers: I07005 FUO TEP
First Submitted: September 10, 2010
First Posted: September 14, 2010
Last Update Posted: February 19, 2014
Last Verified: October 2012

Keywords provided by University Hospital, Limoges:
FDG-PET/CT
FUO
Chronic Inflammatory syndrome
Fever of unknown origin

Additional relevant MeSH terms:
Fever
Body Temperature Changes
Signs and Symptoms